Program
PKN605
A development code.
In Novartis's pipeline, HDAC6 Inhibitor
. Its studies are mostly in Renal Insufficiency · Atrial Fibrillation, led by Novartis.
Furthest: phase 2, since Oct 14, 20252 company-led studies, 2 open or runningNext primary completion: Mar 1, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 22 open or running | phase 2since Oct 14, 2025 | Oct 14, 2025 | Mar 1, 2027phase 1 · NCT07797322 |
- Named in Novartis’s own pipeline as
PKN605
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2025First study: phase 2 study in Atrial FibrillationFirst studyNCT07217067 · 165 planned · United States, Canada, China and more
- Aug 26, 2026Phase 1 study in Renal InsufficiencyNCT07797322 · 40 planned · United States
Ahead
- Mar 1, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07797322
- Sep 9, 2027Primary completion: phase 2 study in Atrial FibrillationNCT07217067
TargetBeta
“HDAC6 Inhibitor”the company's pipeline, read by Claude · source
Other programs on HDAC6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Vorinostatrule | Merck | phase 3 | 29 |
| givinostatrule | Italfarmaco | phase 3 | 23 |
| givinostat hydrochloriderule | Italfarmaco | phase 2 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07797322Renal Insufficiency · United States | 1 | Recruiting | Mar 1, 2027 | 40 |
| NCT07217067Atrial Fibrillation · United States, Canada, China and more | 2 | Recruiting | Sep 9, 2027 | 165 |
How it is read
Names in the registry
- “PKN605”, 2 entries
Codes read as this program: PKN605.
Conditions, from the studies’ own filings
- Renal Insufficiency, 1 study
- Atrial Fibrillation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.